Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
Secondary malignancies like indolent CD4+ CAR T-cell lymphoma can emerge after CAR T-cell therapy. This case highlights the importance of recognizing and thoroughly investigating these rare complications.
Hematology/Oncology June 17th 2024
MDLinx
In a significant stride toward personalized medicine, researchers have utilized AI to unveil two distinct evotypes of prostate cancer, heralding a new era in the disease’s diagnosis and management. This pivotal discovery opens doors to tailored treatment strategies, potentially mitigating the adverse effects of over-treatment in prostate cancer.
Hematology/Oncology March 25th 2024
Roswell Park
Recent advancements in cancer research reveal the potential of using the immune system’s response to activated retrotransposons for early detection of cancers such as lung, pancreatic, and ovarian. This innovative approach could revolutionize cancer diagnostics.
Hematology/Oncology January 22nd 2024
A recent study conducted in Iceland has revealed that approximately 4% of the population carries at least one actionable genotype, which is associated with a reduced life span.
All Specialties November 15th 2023
Discover how a study from USC reveals that the most common genetic cause of ALS and FTD may have its roots in embryonic development, offering new avenues for early diagnosis and treatment.
Neurology August 30th 2023
Dana-Farber Cancer Institute
Explore the potential of OncoNPC, an AI model that leverages gene sequencing data to predict the primary source of cancer, offering a new avenue for more targeted and effective treatments.
Hematology/Oncology August 29th 2023